PDS Biotechnology Corp Business Acquisition, Pro Forma Net Income (Loss)
PDS Biotechnology Corp (PDSB) reported Business Acquisition, Pro Forma Net Income (Loss) of -$31.13 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2021-03-18
- PDS Biotechnology Corp business acquisition, pro forma net income (loss) for the quarter ending 2019-12-31 was -$17.51M.
- PDS Biotechnology Corp business acquisition, pro forma net income (loss) for the quarter ending 2019-09-30 was -$16.55M.
- PDS Biotechnology Corp business acquisition, pro forma net income (loss) for the quarter ending 2019-06-30 was -$14.69M.
- PDS Biotechnology Corp business acquisition, pro forma net income (loss) for the quarter ending 2019-03-31 was -$15.71M.
- PDS Biotechnology Corp business acquisition, pro forma net income (loss) for fiscal 2019 was -$31.13M.
- PDS Biotechnology Corp business acquisition, pro forma net income (loss) for fiscal 2018 was -$44.70M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$17.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$34.07M derived: sum of 2 quarters · filed 2021-03-18 | -$48.75M derived: sum of 3 quarters · filed 2021-03-18 | -$31.13M 10-K · filed 2021-03-18 |
| 2019-09-30 | -$16.55M 10-Q · filed 2019-11-07 | -$31.24M derived: sum of 2 quarters · filed 2019-11-07 | -$13.62M 10-Q · filed 2019-11-07 | -$51.86M derived: sum of 4 quarters · filed 2020-03-27 |
| 2019-06-30 | -$14.69M 10-Q · filed 2019-08-01 | -$19.81M 10-Q · filed 2019-08-01 | -$35.31M derived: sum of 3 quarters · filed 2020-03-27 | -$40.28M derived: sum of 4 quarters · filed 2020-03-27 |
| 2019-03-31 | -$15.71M 10-Q · filed 2019-05-14 | -$20.62M derived: sum of 2 quarters · filed 2020-03-27 | -$25.60M derived: sum of 3 quarters · filed 2020-03-27 | -$38.84M derived: sum of 4 quarters · filed 2020-03-27 |
| 2018-12-31 | -$4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | -$9.88M derived: sum of 2 quarters · filed 2020-03-27 | -$23.13M derived: sum of 3 quarters · filed 2020-03-27 | -$44.70M 10-K · filed 2020-03-27 |
| 2018-09-30 | -$4.98M 10-Q · filed 2019-11-07 | -$18.22M derived: sum of 2 quarters · filed 2019-11-07 | -$39.80M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | -$13.25M 10-Q · filed 2019-08-01 | -$34.82M 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | -$21.58M 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |